Member Info for mulledwine

yes looking not too bad - debt free as well - the cash figure is shown in $ whereas the money raised is shown in £. So roughly $3.36M was raised in Feb ( assuming $1.6 to th £1.) If we had $2.6M left in June then a very rough figure is a $760k cash burn / per 4 months....

Commenting on the announcement today, John Devane, CEO of AGI stated; "The first six months of 2011 saw AGI take its first steps to rebuilding the product pipeline and steering the Company towards being a specialist development company with an emphasis on Orphan needs and critical care applications. We are encouraged with our progress to date."

Operational summary · During the first six months of 2011 AGI began implementing its new strategy announced in late 2010. The Company has re-focused its research and development efforts in the area of specialty indications with unmet medical needs, with particular focus on treatments which qualify for Orphan drug status. · The first six months of 2011 were dominated by the pre-clinical evaluation of AGI-350,, a novel presentation of an existing marketed drug which AGI is developing to treat a significant unmet medical need in the critical care setting. · AGI has completed preliminary development and in-vitro evaluation of a form and formulation of AGI-350 which is specifically designed to provide effective and efficient delivery of the drug to the lung. · AGI entered into a technology access agreement with Aerogen Ltd. to provide specialized aerosol technology for the administration and delivery of AGI-350 to ventilated patients in the Intensive Care Unit (ICU) setting. This proprietary technology is being customized for use with AGI-350 in the target patient population and prototypes have been developed for pre-clinical evaluation. · Furthermore, AGI has initiated a pre-clinical programme for AGI-350 which is ongoing. A model of the target condition has been developed and is being employed to characterise AGI-350 and generate key proof of concept data to inform subsequent clinical development. Once this phase of evaluation is completed in H2 2011, AGI will consider the next steps for this programme, which may involve advancing the product into human trials. · AGI continues to explore other opportunities to develop products for use in the critical care setting. Management believes this is an area that is under-served by currently available products. · During the first six months AGI continued to exercise vigilance over the use of its existing cash resources. Total cash absorbed by operations was $0.9 million in the first six months of 2011, a decrease of 18% over the same period in 2010. In addition, since 30 June, AGI reported the sale of certain intellectual property assets, no longer regarded as core, to Warner Chilcott for $300,000. This will result in a gain on disposal of intellectual property of approximately $54,000, which will be recognised in the second half of the year.

Interim financial results for the six months ended 30 June 2011 Dublin, Ireland, 7 September 2011 - AGI Therapeutics plc ("AGI" or "the Company") (AIM, ESM: AGI), a speciality pharmaceutical development company, today announces interim financial results for the six months ended 30 June 2011. Financial summary · Cash and short-term deposits at 30 June 2011 of $9.3 million (31 December 2010: $10.0 million) · R&D spend $0.7 million (2010: $0.9 million) · G&A spend $0.5 million (2010: $0.6 million) · Loss per ordinary share $0.015 (2010: $0.046)

http://www.investegate.co.uk/Article.aspx?id=201109070700107451N

"This first pass of the underground exploration program has been a success. We've now extended the South Mine Complex east onto the HM claim as well as identified new high grade veins to form the basis for future drilling," said Stewart Carmichael, Chief Exploration Geologist for KL Gold. Charles Page, President and CEO of Queenston commented, "We are pleased with the first phase of underground drilling on the HM property where all three holes intersected high grade mineralization. The strong results show the South Mine Complex remaining open to the east and now drilling will begin to target the AK joint venture property to the south."

Kirkland Lake Gold-Queenston Joint Venture Report New Drill Results; 0.44 Ounces of Gold per Ton Over 22.1 Feet TW, SMC Extended East TORONTO, ONTARIO--(Marketwire - Sept. 7, 2011) - Kirkland Lake Gold Inc. ("KL Gold") (TSX:KGI)(AIM:KGI) and Queenston Mining Inc. ("Queenston") (TSX:QMI)(FRANKFURT:QMI)(STUTTGART:QMI) are pleased to announce the results from the recently completed drilling on the jointly held (50%-50%) South Claims and HM Claim Joint Venture properties within the South Mine Complex ("SMC") located south of KL Gold's Macassa Mine in Kirkland Lake, Ontario. Previous joint venture drilling results were reported in a news release dated September 20, 2010. The HM claim was jointly purchased by KL Gold and Queenston in 2009 (see KL Gold and Queenston press releases dated February 12, 2009). The HM claim is subject to net smelter return royalties of 3%. Three new underground diamond drill holes (totalling 5,930 feet) were completed from the east end of KL Gold's 5300 level drift along the South Claims boundary. All three drill holes intersected the New South Zone, two of which returned significant assays. In addition, all three holes intersected various high grade footwall mineralization including 3.18 ounces of gold per ton ("opt") over a core length of 1.3 feet (hole 53-1823), 2.48 opt over a core length of 1.0 feet, 7.79 opt over a core length of 1.0 feet and 0. 25 opt over a core length of 7.2 feet (hole 53-1824) and 1.14 opt over a core length of 1.9 feet (hole 53-1825) These footwall zones may be related to the SMC however, further drilling is

http://www.investegate.co.uk/Article.aspx?id=20110907070000M9852

Randy Bartley, Chief Executive Officer of Coastal Energy, commented: "We are very pleased with the results of the Bua Ban North A-05 well. This well was drilled as far north as possible to test the presence of hydrocarbons between Bua Ban North A & B. We have several locations identified which are further south and up to 200 feet structurally higher which we plan to test with the upcoming wells. "Total production from Bua Ban North B has come in above our expectations and the wells continue to perform better than expected. We are working to resolve mechanical production issues at Songkhla and expect to restore production to previous levels in the coming weeks. "We expect production facilities to be on location at Bua Ban North A in late October."

Coastal Energy Announces Successful Drilling Results at Bua Ban North A and Operations Update Coastal Energy Company (the "Company" or "Coastal") (TSX: CEN) (AIM: CEO) announces the successful results of the Bua Ban North A-05 well and provides an operations update. The Bua Ban North A-05 well was drilled to a total depth of 5,650 feet TVD. The well encountered 81 feet of gross sand and 35 feet of net pay in the Miocene reservoir with 27 percent average porosity. The well tested the Miocene reservoir on the eastern flank of the Bua Ban North A field. The oil water contact in the well was seen at 3,770 feet. The results of the A-05 well add an additional 1,200 acres to the structural closure area. The Company is planning to drill five to six additional evaluation wells at Bua Ban North before moving the rig to G5/50. The Bua Ban North B-02, B-03 and B-04 wells have all been completed and tied into the production facilities. The aggregate production rate from Bua Ban North B is approximately 8,200 bopd. Average production at Songkhla A is approximately 4,000 bopd, with production currently being constrained due to a temperature issue. The Company is installing additional cooling units to remedy this issue and restore production to 6,500 bopd. The installation is expected to be complete in approximately two weeks. Aggregate offshore oil production is averaging 13,700 bopd, and total Company production is averaging 15,800 boepd.

http://www.investegate.co.uk/Article.aspx?id=201109070700147560N

http://www.investegate.co.uk/Article.aspx?id=201109060700126708N

Havelock Europa reduces losses Date: Tuesday 06 Sep 2011 LONDON (ShareCast) - Shopfitter Havelock Europa reduced half year losses, increased revenue and said it made progress in securing new business in overseas markets. Group revenue increased by 4% to £42.9m in half year to 30 June 2011. Havelock reported a pre-tax loss of £1.5m compared to a loss of £4.6m in 2010 following exceptional costs of £2.1m. Group net debt was reduced to £17.2m from £19.7m in December 2010. CEO Eric Prescott said he was pleased with the progress made across the entire group and noted the good growth internationally. "We continue to work closely with strong blue chip partners," he said. Revenue in Educational Supplies fell 6% to £3.8m. Interiors revenue in the Interiors business rose by 9% to £29.1m. Point of Sale Printing revenue fell slightly to £10.0m from £10.5m a year earlier, reflecting the ending of its contract to supply Somerfield which following the takeover by the Co-op. Havelock also confirmed that appointment of Paul Davis as business development director As previously announced, the board has not recommended any dividend payout in 2011.

http://www.investegate.co.uk/Article.aspx?id=201109060700126706N

McBride has own brand of downturn Date: Tuesday 06 Sep 2011 LONDON (ShareCast) - Own label goods maker, McBride, saw profits halved in the year to end of June as rising costs and a tough retail environment took their toll. The firm, which manufactures household and personal products for retailers to sell under their own names, saw pre-tax profits plummet 49% to £22.5m. It also said that it faced "aggressive competition" from branded rivals. McBride maintained its full year dividend at 6.8p per share. Both its UK and Western Contintal Europe divisions saw revenues fall, however business in Central and Eastern Europe was more robust, with revenues up 18%. Chief executive, Chris Bull, said a weak consumer environment and raw material inflation would continue to present a challenge in the short term. "We believe that the actions we are taking will enable us to become more efficient and therefore better able to realise the potential for Private Label," he said.

http://www.investegate.co.uk/Article.aspx?id=201109061049116970N

LMS stays in one piece Date: Tuesday 06 Sep 2011 LONDON (ShareCast) - Shares in investment firm LMS Capital jumped 10% after news it would not be broken up, despite demands from a substantial minority of shareholders, including its chairman. LMS said that shareholders holding around 35% of the firm's share capital had called for the company to be dismantled in the short term. The firm said having considered the request "and taken independent financial advice from Quayle Munro Limited, the directors, by a majority of six to two...do not believe that a break-up of the company at this time would be in the best interests of shareholders as a whole". It said LMS' revised strategy to pursue direct investments in growing, profitable businesses primarily in the energy, consumer and business services sectors, had seen significant progress since August 2010, including owned EBITDA increasing 42% for the six months to the end of June. The board has now appointed an independent committee comprising the non-executive directors and excluding its chairman, Robert Rayne, to consider its next moves in relation to the break-up demand.

http://www.investegate.co.uk/Article.aspx?id=201109060700106695N

Investors happy as Alumasc confirms dividend By Michael Millar Date: Tuesday 06 Sep 2011 LONDON (ShareCast) - Building and engineering products company, Alumasc, impressed investors with a 55% increase in profits in the year to the end of June. The firm also confirmed an unchanged final dividend of 6.75p per share, giving a total for the year of 10p per share. There had been fears that a deterioration in margins would see the firm cut its payout for shareholders. Pre-tax profits came in at £5.4m, which combined with the news of the dividend, sent shares up 6% in morning trading. Profits were driven by the firm's Alumasc Precision division, which benefitted from strong export demand from companies serving mining and construction sectors in emerging markets. Chairman, John McCall, said it had been a year of stark contrasts for UK business. "Early cycle businesses, such as precision engineering, where customers react swiftly to change in economic conditions, experienced strong recovery as distribution pipelines were replenished and global development programmes resumed," he said. "In contrast, those businesses with longer lead times, such as construction, continued to experience decline in demand as completed projects outstripped new work." The cut-back in public expenditure in the UK intensified this contrast, he added, with revenues from building products missing expectations, despite growing by by 10% to £71.2m. Overall, full year group revenues from continuing operations grew by £19.3m, or 22%, to £106.8m.

Dechra Pharmaceuticals shrugs off weak economy Date: Tuesday 06 Sep 2011 LONDON (ShareCast) - The reluctance of pet-owners’ to neglect their animals despite tough economic conditions helped Dechra Pharmaceuticals post a rise in profits in the year to 30 June. Pre-tax profits climbed to £18.5m from £17.7m the previous year on revenues up to £389.2m from £369.4m. The full-year dividend rises to 12.1o from 10.5p. “Although footfall through veterinary practices has declined and the general economic climate remains uncertain we are continuing to demonstrate solid growth in markets in which we trade,” the company said. “Our branded product range, the focus of our key strategic objective, continues to grow strongly.” Dechra’s brands include DermaPet, a pet dermatological business acquired in October and Genitrix, which was acquired in December and makes canine epilepsy treatments.